These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 28375404)

  • 1. Hot Topics in Primary Care: Demystifying the Differences: Follow-on Biologics, Biosimilars, and Generics.
    Wright EE; Blevins TC; Reed B; Pollom RD
    J Fam Pract; 2017 Apr; 66(4 Suppl):S22-S27. PubMed ID: 28375404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
    Falit BP; Singh SC; Brennan TA
    Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The US approach to biosimilars: the long-awaited FDA approval pathway.
    Calvo B; Zuñiga L
    BioDrugs; 2012 Dec; 26(6):357-61. PubMed ID: 23030677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilars in Oncology in the United States: A Review.
    Nabhan C; Parsad S; Mato AR; Feinberg BA
    JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacovigilance of biosimilars - Why is it different from generics and innovator biologics?
    Oza B; Radhakrishna S; Pipalava P; Jose V
    J Postgrad Med; 2019; 65(4):227-232. PubMed ID: 31571620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On safety margin for drug interchangeability.
    Zheng J; Chow SC; Song F
    J Biopharm Stat; 2017; 27(2):293-307. PubMed ID: 27911675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilar safety factors in clinical practice.
    Reinisch W; Smolen J
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BIOSIMILAR DRUGS ARE NOT GENERICS.
    Zangeneh F; Dolinar R
    Endocr Pract; 2016 Jan; 22(1):6-7. PubMed ID: 26731083
    [No Abstract]   [Full Text] [Related]  

  • 9. Current Japanese Regulatory Systems for Generics and Biosimilars.
    Kuribayashi R; Sawanobori K
    J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilar drugs : concerns and opportunities.
    Genazzani AA; Biggio G; Caputi AP; Del Tacca M; Drago F; Fantozzi R; Canonico PL
    BioDrugs; 2007; 21(6):351-6. PubMed ID: 18020619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
    Gonçalves J; Araújo F; Cutolo M; Fonseca JE
    Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A GUIDE TO FOLLOW-ON BIOLOGICS AND BIOSIMILARS WITH A FOCUS ON INSULIN.
    Dolinar R; Lavernia F; Edelman S
    Endocr Pract; 2018 Feb; 24(2):195-204. PubMed ID: 29466056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars: the need, the challenge, the future: the FDA perspective.
    Epstein MS; Ehrenpreis ED; Kulkarni PM;
    Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why are biosimilars much more complex than generics?
    Pagani E
    Einstein (Sao Paulo); 2019 Feb; 17(1):eED4836. PubMed ID: 30810585
    [No Abstract]   [Full Text] [Related]  

  • 15. Global regulatory standards for the approval of biosimilars.
    Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
    Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating AE Reporting of Two Off-Patent Biologics to Inform Future Biosimilar Naming and Reporting Practices.
    Stergiopoulos S; Getz K
    Drug Saf; 2015 Aug; 38(8):687-92. PubMed ID: 26108298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars: The US Regulatory Framework.
    Christl LA; Woodcock J; Kozlowski S
    Annu Rev Med; 2017 Jan; 68():243-254. PubMed ID: 27813877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stakeholders discuss biosimilar naming, substitution.
    Traynor K
    Am J Health Syst Pharm; 2014 Mar; 71(6):446-7. PubMed ID: 24589534
    [No Abstract]   [Full Text] [Related]  

  • 19. Similar names for similar biologics.
    Casadevall N; Felix T; Strober BE; Warnock DG
    BioDrugs; 2014 Oct; 28(5):439-44. PubMed ID: 25001080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars for Immune-Mediated Chronic Diseases in Primary Care: What a Practicing Physician Needs to Know.
    Feldman SR; Bagel J; Namak S
    Am J Med Sci; 2018 May; 355(5):411-417. PubMed ID: 29753369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.